Shares of Boston Scientific BSX moved higher by 0.6% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 79.49% year over year to $0.08, which beat the estimate of ($0.03).
Revenue of $2,003,000,000 declined by 23.87% year over year, which beat the estimate of $1,710,000,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Jul 29, 2020
Time: 08:00 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/514/35543
Price Action
52-week high: $46.62
52-week low: $24.10
Price action over last quarter: Up 2.19%
Company Profile
Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract tests, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
